Compare MetLife Inc. Common Stock (MET) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MetLife Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? MetLife Inc. Common Stock trades at $100.15 (market cap $63.96B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: MetLife Inc. Common Stock is far larger — about 17.1× Tango Therapeutics Inc.'s market cap, and MetLife Inc. Common Stock pays a 2.35% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold MetLife Inc. Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| MET | TNGX | |
|---|---|---|
Market Cap | $63.96B | $3.75B |
Volume | 3,016,459 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $100.65 | $32.90 |
52-Week Low | $67.70 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $84.89B | $2.77B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MetLife (MET) trades at $100.65, up 0.48% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with a P/E of 19.28 and a net income margin of 4.66%. Recent news highlights a declared dividend of $0.59 per share and upcoming Q3 2026 results.
The outlook for MET is positive, driven by earnings momentum and a favorable interest rate environment for insurers. Key risks include investment income volatility and competitive pressures. With a consensus price target of $108.25 and no sell ratings, Wall Street sentiment remains bullish, though the stock's RSI suggests potential near-term overbought conditions.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MetLife Inc. Common Stock
MetLife provides insurance, annuities, employee benefits, and asset management services. Its products serve individuals, employers, and institutions.
Read more on MET →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
